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ABSTRACT Molecular physiology is a new interdisciplinary field of knowledge that looks into how complicated 
biological systems function.  The living cell is a relatively simple, but at the same time very sophisticated bio-
logical system. After the sequencing of the human genome, molecular physiology has endeavored to investigate 
the systems of cellular interactions at a completely new level based on knowledge of the spatial organization 
and functions of receptors, their ligands, and protein-protein interactions.  In recent years, the achievements in 
molecular physiology have centered on the study of sensor reception mechanisms and intercellular data transfer, 
as well as the immune system physiology, amongst other processes.
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ABBREVIATIONS BPA - Benign prostatic adenoma, PIN – Prostatic Intraepithelial Neoplasia, PSA – Prostate-
specific antigen, PC – prostate cancer, cAMP – cyclic adenosine monophosphate, cGMP – Cyclic guanosine 
monophosphate, АМАCR - Alpha-methylacyl-coenzyme A Racemase, CGI – CpG-island, DAG – Diacylglycerol, 
DD3 - Differential Display Code 3, EPСA - Early Prostate Cancer Antigen, ERG4 – V-ets Erythroblastosis vi-
rus E26 oncogene homolog, ETS – transcription factor, ETV1 – ETS translocation variant 1, EGFR - Epidermal 
Growth Factor Receptor, GSTP1 - Glutathione-S-Transferase π1, IP3 - Inositol Trisphosphate, RARβ2 - Retinoic 
Acid Receptor Beta 2, RASSF1A - RAS Association Domain Family Protein 1A, TMPRSS2 - Transmembrane 
Serine Protease 2
W
hen considering the functioning mechanisms 
of membrane receptor systems, it is neces-
sary to first highlight the achievements in 
molecular physiology regarding the process regula-
tion that occurs in the cell, as well as the intracellular 
transmission of hormonal signals. The concept of sec-
ondary messengers (secondary mediators) is considered 
today fundamental in cellular and physical-chemical 
biology, as well as in molecular medicine. However, to-
wards the end of the 1950s the discovery of the first 
biologically active substance with signal-transduction 
functions – cAMP – had upended concepts regarding 
biochemical process regulation in the cell and the intra-
cellular mechanisms of signal transduction. It appears 
that the signal molecules not able to cross through the 
cellular membrane interact with the specific receptors 
and enzyme systems located on the membrane’s ex-
ternal surface. Thus, through interaction with mem-
brane receptor systems, biologically active substances 
determine the production of one or several secondary 
messengers; low-weight biologically active molecules 
which transmit signals on intracellular effector struc-
tures. Currently, more than 10 similar molecules have 
been described – they are as follows: cyclic nucleotides 
cAMP and cGMP; inositol exchange products – inositol 
phosphate (IP3); diacylglycerol (DAG), as well as Ca2+ 
ions; polynucleotide oligoA; nitrogen monoxide (NO); 
arachidonic acid exchange products; and a number of 
other substances of lipid-origin (Fig. 1).
It appears that key stages in signal transduction 
mediated by secondary messengers are common to 
regulation systems: agonist – receptor- effector pro-
tein- secondary messenger- modulating protein com-
ponent – physiological response. The main features of 
secondary messengers are their universality and trig-
ger functions.  Furthermore, both various molecular 
structures (e.g., ion channels) and multistage cascades 
of enzymatic reactions can act as effectors and their 
regulation systems.
In the second half of the 20 th century, not a single 
Nobel Prize was awarded for the outstanding achieve-
ments in research concerning this group of biological-
ly active compounds. In various years, E. Sutherland, 
E. Fischer and E. Krebs, F. Gilman and M. Rodbell, F. 
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Grignard, L. Ignarro, R. Furchgott and F. Murad et al. 
were awarded Nobel prizes.  It should be noted that the 
main achievements in molecular physiology are in some 
way linked to cell surface receptors. Studies focusing 
on central nervous system neurons, neuron junctions, 
and neural impulse distribution have led to significant 
improvements in our understanding of cell physiology.
Receptors of the cellular membrane can be subdivid-
ed into two basic classes: ionotropic and metabotropic. 
Ionotropic receptors are membrane channels which 
open or close after binding with a ligand. Emerging 
ion streams modulate intracellular ion concentrations, 
which may cause repeat activation of intracellular me-
diators. Metabotropic receptors may be directly linked 
to secondary messenger systems. Conformational 
changes in a receptor during ligand-binding trigger 
initiation of a biochemical reaction cascade, leading to 
changes in the functional state of the cell. Membrane 
receptors play a significant role in intracellular com-
munications, signal transduction into the cell, neural 
impulse transduction, and many other cell functions. 
The variability of receptors to various ligand types rep-
resented on the membrane of the exact cell constitutes 
its receptor profile, which determines the type of phys-
iological activity of that cell (Fig. 2).
It should be noted that the study of the functions of 
a receptor complex not only allows us to understand 
the ‘life’ of a normal cell, but can also shed light on the 
molecular origin of various diseases. On the level of cell 
receptor system functioning, molecular physiology and 
molecular medicine are intrinsically linked. P. Erlich’s 
postulate on the selective effects of curing substances 
on selective targets (1905) served as the starting point 
for pharmacological science – in particular pharma-
cokinetics – in which one of the basic goals is to study 
the receptor mechanisms of curing substance activity. 
Receptor profiles determine not only the functional ac-
tivity of a normal cell, but also the specific pathologi-
cal conditions of the cells and entire organs. In recent 
years, many studies have been devoted to both the re-
ceptor profile and its dependence on pathological proc-
esses in precisely targeted organs.
We have defined the parameters of the main human 
alveolar macrophage receptor systems in both normal 
and pathological conditions [1]. After estimation of the 
examples of ligand dissociation constants, it was shown 
that the physiological constant profiles of pathological 
and normal conditions are substantially different (Fig. 
3). We also compared the enzyme activity of phosphor-
ylation systems in normal cells and human tumor cells.   
It was shown that in normal and tumor cells enzyme 
activity levels substantially differ; the same tendencies 
in studies of kinases are observed for different types 
of tumor cells [2]. An avalanche of experimental data 
relating to the intracellular “machinery” is being ac-
cumulated; specific details of the synapse transduction 
mechanisms, and knowledge on the structure and func-
tions of normal and defect genes and proteins.
The significance of the membrane receptor func-
tions and their spatial localization makes these mol-
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Fig. 1. The main stages of signal transduction mediated by 
secondary messengers in the cell (cAMP - cyclic adenos-
ine monophosphate, cGMP - cyclic guanosine monophos-
phate, DG - diacylglycerol).
Fig. 2. Relation between the receptor portrait of a 
cell and the features of systemic pathologies (GABA - 
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ecules the main targets for the development of drugs 
against a wide range of diseases, including oncology. In 
recent years, one of the brightest achievements in mo-
lecular physiology has been the development of target 
drugs based on “therapeutic” monoclonal antibodies. 
An example of this is trastuzumab, which is based on 
humanized monoclonal antibodies to receptor ErbB2 
(HER2, HER2/neu) of the epidermal growing factor 
family (EGFR). The drug is widely used for the treat-
ment of such diseases as breast cancer, amongst others. 
Humanized monoclonal antibodies specifically bind to 
the extracellular part of the HER2/neu receptor mol-
ecule, and they prevent uncontrolled cell proliferation, 
causing block age of the cell cycle and suppression of 
angiogenesis. Furthermore, when monoclonal antibod-
ies bind to the target cell, the activation of cell immu-
nity and apparent antibody-dependent cytotoxicity are 
observed.
The implementation of a molecular approach, in 
this particular case the use of target drugs based on 
monoclonal antibodies, can considerably improve the 
clinical situation, improve a patient’s quality of life, and 
extend their lifespan. Developing target therapeutic 
drugs being capable of interacting selectively with tar-
gets inside the cell or on its surface is one of the priori-
ties in molecular medicine, since the receptor profile of 
each cell type is unique. This direction is considered to 
have great potential, since irregularities in the activ-
ity of various enzymes or of their regulation is the ba-
sic reason behind metabolic disorders and diseases, as 
enzymes participate in all biochemical reactions and 
are likely to determine the course of pathological proc-
esses. 
Membrane-bound enzymes play a wide range of bio-
logical roles, participate in its main processes, such as 
processing of biologically active molecules, degradation 
of extracellular matrix components, decomposition or 
activation of soluble or surface proteins, cell adhesion, 
and signal transduction into cell. Thus, the activity of 
different proteases, particularly those localized on the 
membrane, is believed to be responsible for the events 
that occur at the early stages of tumor development, 
because of the disturbances in expression regulation 
in enzymes belonging to this class [3–6]. We obtained 
strong evidence of the significance of such an approach 
in studies of prostate cancer (PC) markers.
Prostate cancer is one of the most widespread tumors 
in the male population, characterized by a rapid metas-
tasis process [7]. In countries of the European Union, 
two hundred thousand new cases of prostate cancer 
are diagnosed annually, with a total of forty thousand 
deaths occurring [8]. Here, we approach another aspect 
of molecular physiology and medical intervention – the 
molecular diagnostics of diseases. 
To this date, a large number of genes and their prod-
ucts which are believed to be involved in the develop-
ment of PC have been detected, and they can reason-
ably be considered as markers of this disease [9-14]. 
Changes in prostate tissue during the malignization 
process affect all basic cell functions and are reflected 
on different levels of structures and processes, such as 
cytomorphological changes, changes in the expression 
of genes and their products, epigenetic changes, etc. 
The basic molecular markers, indicating prostate tissue 
malignization, are illustrated in Fig. 4. 
Malignant tumors in the prostate (including PC) 
can cause changes in the genome, a very significant 
occurence.  In particular, changes appear in the DNA 
methylation profile [15–24]. Hypermethylation of the 
5`-regulatory regions of several genes leads to their in-
activation. These changes in genetic material can be 
used in the diagnosis of prostate pathological condi-
tions. 
Amongst the well known epigenetic anomalies is the 
change in the GST1 gene promoter region methylation 
profile, found within tumor cells. This gene encodes cy-
toplasm glutation-S-transferase of the 1 class, which 
participates in apoptosis regulation and xenobiotic 
utilization. Hence, in normal cells of the prostate, the 
promoter region of the GST1 gene is non-methylated, 
whereas upon proliferative inflammatatory atrophy 
(PIA) the methylation frequency of this region in the 
GST1 gene is 6.4%; for highly active prostatic intraepi-
thelial neoplasia (PIN) – 70%; and for prostate adeno-
carcinoma – 90% [25].
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Fig. 3. Binding parameters of various receptors of the hu-
man lung alveolar macrophages with ligands in normal and 
chronic inflammations of the lungs (3H - tritium, DHA, PRZ, 
IMI, QNB - studied ligands, green shows the values of Kd 
for the studied ligands in normal lungs; raspberry - chronic 
inflammation of the lungs).REVIEWS
 VOL. 3  № 1 (8)  2011  | ACTA NATURAE | 23
Changes in the methylation status of the 5’-regu-
latory regions influence not only the GST1 gene, but 
also genes the products of which participate in tumor 
proliferation suppression [26-32]. CGI methylation in 
the promoter regions of such genes causes inactivation, 
which is associated with increased risk of development 
of a malignant tumor:  RAR2 (retinoic acid receptor  2) 
gene encodes the protein responsible for the receptor-
mediated suppression of tumor growth (retinoids are 
well-known inhibitors of tumor growth and progress). 
Methylation of the CpG islands in the promoter region 
of the RAR2 gene indicates prostate tumor maligniza-
tion. In healthy pancreatic tissue, methylation of CpG 
islands is absent [33]. The RASSF1A (RAS association 
domain family protein 1A) gene is also a tumor growth 
suppressor. Methylation of the CpG islands in the pro-
moter region of this gene was detected upon maligni-
zation of various tissue types [34, 35]. The frequency 
and methylation rate of RASSF1A correlate with the 
tumor’s aggressiveness, allowing for an adequate prog-
nosis of the outcome of a disease [36].
A number of studies performed earlier indicate the 
key role of DNA damage in the development of the ma-
lignization process. The most significant among these 
damages is considered to be the emergence of multi-
ple chromosome rearrangements and mutations in tu-
mor tissues. Genome instability is a common feature 
of tumor cells which manifests itself on the level of 
both chromosomes and selected genes. Moreover, each 
type of tumor is characterized by an assigned set of the 
most widespread disorders. In the tumor tissue, a high 
number of structural rearrangements can be found; 
firstly, translocations and deletions, the quantity of 
which significantly rises as the tumor progresses. 
The level of transcripts consisting of the 5’-untrans-
lated region of the androgen-regulated gene TMPRSS2 
and exones of the genes of the  ETC (ERG4 or ETVI) 
family is considerably higher in tumor cells [37]. Rear-
rangements affecting the TMPRSS2 gene and genes of 
the transcription factors ETC (ERG4, ETVI, ETV4, etc.) 
occur in prostate tumor cells. These rearrangements 
result in the generation of chimera oncogenes [38, 39]. 
Androgen-dependent promoter elements ensure a high 
level of expression of such chimera oncogenes [38, 39]. 
It is necessary to note that there is a positive correla-
tion between the presence of the chimera TMPRSS2-
ETC gene transcript and disease severity. A high fre-
quency of detection (50 –60%) is characteristic for 
mRNA of this chimera gene in prostate adenocarcino-
ma; whereas for PIN, this value is 16%; and in normal 
tissue, it is 4%.
During the early stages of the disease (when the 
tumor process is localized), PC is comparably easy to 
cure; however, as a result of a shortage of diagnosis 
methods, tumors are usually detected during the final 
stages of the disease. The current methods are either 
insufficiently informative or traumatic. Some recent 
scientific publications reveal losses of some prognostic 
significance of the basic, presently used biochemical 
tests for PC – PSA (determination of the prostate-
specific antigen concentration in blood). In medical 
practice false negative and false positive diagnoses 
based on PSA determination occur frequently. The 
preliminary diagnosis is confirmed by biopsy; a rather 
painful procedure with negative consequences for the 
general condition of the prostate. Thus, the basic goal 
of a diagnosis is not simply to confirm the disease, but 
also to reveal the pathogenic process at the earliest 
possible stage and to determine the stage of the tu -
mor’s progression.
Many types of biochemical markers of PC have been 
described; those originating from serum, urine, semen 
and prostate tissues. Only a few of these markers can 
be used in clinical practice, and only one has made it 
to the clinical trial phase. The markers GSTP1, DD3, 
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Fig. 4. Some markers of prostate cancer and their locali-
zation in the cell (PSA - prostate specific antigen, DD3 
- differential display code 3, p53 - protein 53, RARβ2 - 
retinoic acid receptor beta2, Trp-p8 - transient receptor 
potential-p8, AZGP - zinc a-2-glycoprotein 1, RASSF1A - 
RAS association domain family protein 1A, ECAD - E-cad-
herin, Hk2 - human prostate specific glandular kallikrein, 
MUC1 - mucin 1, AMACR - a-methylacyl-coenzyme A 
Racemase, n - nuclear, c - cytoplasmic, s - soluble, tm - 
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AMACR, EPCA, and hepsin are among those showing 
the most promise. As previously stated, the expres-
sion level of hepsin (limited in a normal cell) rapidly 
increases in a progressing tumor. It is necessary to note 
that the specificity of high expression levels of hepsin 
by tumor cells had attracted attention at the earliest 
stages of the study of that protein. Expression of this 
enzyme increases as the tumor progresses and reaches 
a maximum at terminal stages (Fig. 5) [40]. 
Thus, because of the high specificity of hepsin ex-
pression in tumor cells, there is an opportunity to an-
swer the question as to whether the neoplasm in pros-
tate is benign or malignant. Hepsin is preferable to the 
molecular markers currently being used in clinical 
practice in terms of several parameters.  We propose 
the following hypothesis:  an increase in hepsin proteo-
lytic activity on a cell surface is specific of prostate tu-
mors. For a confirmation of this hypothesis, we obtained 
a producer strain of recombinant hepsin and found the 
most specific substrate for it via a process of perfect 
purification and activation procedures [41]. We proved 
that it is possible to determine the proteolytic activ-
ity in biomaterial samples obtained from males with 
various pathological conditions of prostate, selected the 
conditions of this analysis, and we confirmed its specifi-
city in the case of a tumor. The resulting data testifies 
to the fact that proteolytic activity in a conditionally 
healthy donor group is similar to that in a group of pa-
tients with chronic prostatitis and BPH; but it reliably 
differed from the proteolytic activity in a group of pa-
tients with prostate adenocarcinoma (Fig. 6).
This fact confirms the high specificity of the meth-
od:  whilst chronic prostatitis and the BPH background 
level of proteolysis activity are constant (as in condi-
tionally healthy patients), the PC progress level of pro-
teolysis activity rapidly increases, and the basic impact 
includes hepsin, so far as a specific substrate is used for 
detection [42].
Based on the studies carried out in our laboratory, 
a PC detection test-kit has been developed. It is based 
on hepsin activity determination in epithelial cells of 
the prostate collected with urine after rectal massage 
(Patent “Prostate cancer detection test-kit and prostate 
cancer diagnostic method” [Eurasian patent № 011694], 
diagnostic kit (Registration № FSR 2009/05065)). Such 
parameters as sensitivity, specificity, prognostic signif-
icance of positive and negative results, and diagnostic 
accuracy of the developed method are not inferior to 
those of the well-known biochemical tests for PC and 
other methods currently under development; indeed, 
it proved better by some parameters (Fig. 7).
Besides, the new method has significant advantages 
in comparison with the currently widely used PSA con-
centration determination methods. 
The method presented by us is better than existing 
ones, because of the non-invasive character of bioma-
terial collection; since enzyme activity is measured in 
urine.  To conclude, application of this method, which 
was developed in conjunction with existing methods, 
will help to avoid false diagnosis and will have a ben-
eficial impact on the general conditions and quality of 
life of the patient. 
а b
SRCR domain
Serine protease domain
Active site pocket
Extracellular
Intracellular
18–44
1–17
Normal prostate
Benign prostatic 
hyperplasia
Prostate cancer 
Gr. II/III
Prostate cancer 
Gr. IV/V
Fig. 5. a - Histochemi-
cal staining of sections 
of prostate tissue from 
patients with prostate dis-
eases of varying severity 
with monoclonal antibod-
ies against hepsin (color 
intensity correlates with 
the expression level of 
hepsin on the cell sur-
face). b - Domain struc-
ture of hepsin and location 
of the protein relative 
to the cell membrane 
(green shows the plasma 
membrane and the active 
center of hepsin; blue - 
SRCR-domain of hepsin; 
violet - protease domain 
of hepsin).REVIEWS
 VOL. 3  № 1 (8)  2011  | ACTA NATURAE | 25
The results obtained allow to conclude that the 
new method of malignant neoplasm of prostate di -
agnostics with determination of hepsin activity has 
a set of advantages as compared with the currently 
widely used PSA determination and can be recom -
mended for PC screening studies in clinical labora-
tory conditions.
Increase of the size of a tumor as a result of increas-
ing, uncontrollable tumor cell proliferation causes them 
to invade surrounding tissues. This process is followed 
by the end of any contact both between tumor cells and 
normal cells; because of the action of various trans-
membrane proteases, it affects the surrounding ter-
ritorial matrix, as well. 
Serine protease hepsin is one of the enzymes that 
regulate the process of local invasion of tumor cells [4]. 
The expression level of hepsin was shown to considera-
bly increase on the surface of prostate adenocarcinoma 
cells [43-47]. Hepsin was shown to be the key activa-
tion factor of the proteolytic processes in tumor tissue, 
which result in dissemination of tumor cells.  In order to 
better understand the role of hepsin in these processes, 
it would help to review how the associated membrane 
proteolysis participates in the tumor’s progress. Dur-
ing the pathological process, activity of the membrane-
bound proteases causes an uncontrollable proteolysis of 
the territorial matrix and disorganization of its struc-
ture. 
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Fig. 7. Comparative analysis of the basic evaluative diag-
nostic indexes of the methods for prostate diseases diag-
nosis - determination of the concentration of PSA in the 
blood of the patient and determination of hepsin activity 
using “PHOTO-HEPSIN” (red shows the values of “PHOTO 
HEPSIN” parameters; blue shows the values of the pa-
rameters of the method for PSA concentration determina-
tion; -PV - negative predictive value; and  +PV - positive 
predictive value).
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The majority of studies devoted to evaluating the 
role of hepsin in oncopathology have focused on tumors 
of the prostate. We shall review the basal membrane 
disorder of this organ from the perspective of molecu-
lar physiology and the potential role of hepsin. The ba-
sal membrane of the prostate is a specialized extracel-
lular structure separating epithelial and stromal cells 
from each other and consisting of the matrix proteins 
produced by these two cell types [48].  Disruption of this 
structure is necessary for a local invasion in the early 
metastasis process [49].The molecular mechanisms in-
volving hepsin in the progress of malignant neoplasm 
has become clear. The set of extracellular matrix com-
ponents which are potential hepsin substrates have 
been discovered [4, 50].
Another aspect of hepsin’s impacts on the pathologi-
cal process is the activation of enzymes in inactive form 
that are also involved in the process of basal membrane 
degradation [51]. Thus, hepsin can multiply and in-
crease proteolysis on the surface of tumor and stromal 
cells, which aggravates the damage to the basal mem-
brane and accelerates tumor progress (Fig. 8).
This hypothesis confirms the data on the suppression 
of the tumor cell’s invasive growth when hepsin activ-
ity is inhibited [52]. This, and other features of hepsin, 
makes it a convenient target for therapeutic actions. 
Therefore, studying the inhibition mechanisms is con-
sidered promising in the development of antitumor 
drugs that can be effective in case of tumors for which 
an elevated expression of hepsin is characteristic. The 
search for specific hepsin inhibitors is underway, with 
the purpose of creating targeted drugs and develop-
ing PC therapy methods [53]. Hepsin is involved in such 
phenomena as the increase in cell motility, matrix pro-
tein separation and extracellular structure disorganiza-
tion, and activation of extracellular proteases and their 
cascades, which underlie tumor progression. Inhibition 
of the activity of this enzyme may lead to suppression 
of these processes, and it will positively influence  dis-
ease outcome.
In 2008, in a  screening of the libraries of drugs and 
various chemical compounds aimed at searching for 
potential low-molecular-weight inhibitors of hepsin, a 
set of compounds capable of specifically inhibiting its 
proteolytic activity were found. Anthralin (anthracene-
1,8,9-triol) emerged as  one of the most efficient inhibi-
tors of hepsin. Some compounds were dose-depend-
ently shown to suppress the activity of recombinant 
hepsin and to exhibit no cytotoxic effect on various cell 
lines, which is significant for therapeutic applications. 
Among all compounds, anthralin demonstrated the 
highest inhibiting ability towards hepsin: it inhibited 
hepsin 5.5 and 85 times more efficiently than trypsin 
and thrombin, respectively [53].
As was discovered earlier in our laboratory, anthra-
lin inhibits recombinant hepsin. Due to this, we as -
sumed that anthralin may affect the native form of the 
protein in the same way [41]. The main contribution to 
proteolytic activity on the surface of prostate adeno-
carcinoma cells is made by hepsin, since it is its gene 
that is over-expressed. Therefore, it can be assumed 
that the impact of a specific hepsin inhibitor will con-
siderably decrease the general proteolytic activity. The 
introduction of Anthralin into lysated human prostate 
adenocarcinoma cells caused a 50–70% reduction in the 
general proteolytic activity, which attests to the fact 
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W
hen considering the functioning mechanisms 
of membrane receptor systems, it is neces-
sary to first highlight the achievements in 
molecular physiology regarding the process regula-
tion that occurs in the cell, as well as the intracellular 
transmission of hormonal signals. The concept of sec-
ondary messengers (secondary mediators) is considered 
today fundamental in cellular and physical-chemical 
biology, as well as in molecular medicine. However, to-
wards the end of the 1950s the discovery of the first 
biologically active substance with signal-transduction 
functions – cAMP – had upended concepts regarding 
biochemical process regulation in the cell and the intra-
cellular mechanisms of signal transduction. It appears 
that the signal molecules not able to cross through the 
cellular membrane interact with the specific receptors 
and enzyme systems located on the membrane’s ex-
ternal surface. Thus, through interaction with mem-
brane receptor systems, biologically active substances 
determine the production of one or several secondary 
messengers; low-weight biologically active molecules 
which transmit signals on intracellular effector struc-
tures. Currently, more than 10 similar molecules have 
been described – they are as follows: cyclic nucleotides 
cAMP and cGMP; inositol exchange products – inositol 
phosphate (IP3); diacylglycerol (DAG), as well as Ca2+ 
ions; polynucleotide oligoA; nitrogen monoxide (NO); 
arachidonic acid exchange products; and a number of 
other substances of lipid-origin (Fig. 1).
It appears that key stages in signal transduction 
mediated by secondary messengers are common to 
regulation systems: agonist – receptor- effector pro-
tein- secondary messenger- modulating protein com-
ponent – physiological response. The main features of 
secondary messengers are their universality and trig-
ger functions.  Furthermore, both various molecular 
structures (e.g., ion channels) and multistage cascades 
of enzymatic reactions can act as effectors and their 
regulation systems.
In the second half of the 20 th century, not a single 
Nobel Prize was awarded for the outstanding achieve-
ments in research concerning this group of biological-
ly active compounds. In various years, E. Sutherland, 
E. Fischer and E. Krebs, F. Gilman and M. Rodbell, F. 
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